HTG Competitors

Delisted . USA . 
Stock . HTG Molecular Diagnostics
HTGMDelisted Stock  USD 0.57  0.20  54.05%   
HTG Molecular Diagnostics competes with BioAffinity Technologies,, Precipio, Intelligent Bio, BioAffinity Technologies, and T2 Biosystms; as well as few others. The company conducts business under Health Care Technology sector and is part of Health Care industry. Analyzing HTG Molecular competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of HTG Molecular to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of HTG Molecular competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.570.570.57
Details
Intrinsic
Valuation
LowRealHigh
0.540.540.63
Details
Naive
Forecast
LowNextHigh
0.130.130.13
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.270.450.63
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as HTG Molecular. Your research has to be compared to or analyzed against HTG Molecular's peers to derive any actionable benefits. When done correctly, HTG Molecular's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in HTG Molecular Diagnostics.

HTG Molecular Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between HTG Molecular and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of HTG and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of HTG Molecular Diagnostics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
BIOC
+ 0.89
BIAF
BIOC
+ 0.85
BIAFW
TTOO
+ 0.82
BIOC
BIAFW
+ 0.8
BIAF
TTOO
+ 0.76
BIAF
TTOO
+ 0.73
BIAFW
  
High negative correlations   
IDXG
- 0.44
GTH
PMD
- 0.42
BIAF
SQL
- 0.34
GTH
TTOO
- 0.33
PMD
TTOO
- 0.31
IDXG
BIOC
- 0.29
PMD

Risk-Adjusted Indicators

There is a big difference between HTG Stock performing well and HTG Molecular Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze HTG Molecular's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
GTH  1.87  0.02 (0.02)(2.40) 2.49 
(2.24)
 3.45 
(4.08)
 14.43 
BIAF  3.73 (0.59) 0.00  1.05  0.00 
 0.00 
 11.27 
(7.41)
 32.01 
PMD  1.52  0.41  0.05 (0.57) 3.35 
(2.29)
 1.74 
(1.67)
 57.47 
PRPO  2.18  0.08 (0.01)(0.24) 2.60 
(2.25)
 5.26 
(3.87)
 11.89 
INBS  3.97  0.06  0.04  0.11  4.67 
(4.51)
 9.93 
(7.97)
 25.53 
BIAFW  11.52  0.22  0.03  0.13  13.27 
(15.29)
 28.21 
(26.92)
 83.21 
SQL  4.56  0.09  0.00  3.43  4.49 
(8.97)
 12.50 
(10.64)
 50.87 
IDXG  10.38  2.50  0.21  1.14  9.49 
(14.08)
 18.81 
(16.19)
 194.90 
BIOC  6.16 (2.61) 0.00 (2.01) 0.00 
 0.00 
 9.24 
(15.27)
 66.54 
TTOO  5.35 (2.56) 0.00  28.23  0.00 
 0.00 
 8.70 
(14.29)
 36.38 
All Fundamental Data

HTG Molecular Competitive Analysis

The better you understand HTG Molecular competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, HTG Molecular's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across HTG Molecular's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
HTGM GTH BIAF PMD PRPO INBS BIAFW SQL IDXG BIOC
 54.05 
 0.57 
HTG
 2.08 
 0.94 
Genetron
 1.31 
 0.76 
BioAffinity
 2.30 
 2.67 
Psychemedics
 6.18 
 6.87 
Precipio
 11.39 
 1.76 
Intelligent
 1.64 
 0.60 
BioAffinity
 0.00 
 0.39 
SeqLL
 0.00 
 2.20 
Interpace
 13.28 
 1.45 
Biocept
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Abnormally volatile
Dangerous
Slightly risky
Extremely Dangerous
Out of control
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
OK
Insignificant
Insignificant
Insignificant
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Dangerous
Very High
Dangerous
Very High
High
High
Dangerous
Dangerous
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Buy
Not Available
Strong Buy
Strong Buy
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Strong Sell
Not Rated
Strong Sell
Strong Sell
Strong Sell
Not Rated
Not Rated
Not Rated
Current Ratio
1.9
2.83
0.02
2.06
2.19
2.33
0.02
9.88
0.61
3.38
Net Asset
17.78 M
975.33 M
8.22 M
12.33 M
18.1 M
13.78 M
8.22 M
8.41 M
38.43 M
30.87 M
Profit Margin
N/A
-1.24
-1.19
-0.22
-0.23
N/A
-1.19
N/A
-0.59
N/A
EBITDA
(20.14 M)
(546.24 M)
(7.63 M)
(251 K)
(4.32 M)
(8.81 M)
(7.63 M)
(5.24 M)
(9.12 M)
(31.98 M)
Operating Margin
-3.15
-0.87
-0.87
-0.19
-0.27
-3.86
-0.87
N/A
-0.28
-10.38
Current Valuation
2.56 M
102.87 M
13.03 M
14.22 M
9.82 M
4.42 M
N/A
526.51 K
11.72 M
5.92 M
Price To Book
6.26
1.68
3.87
2.58
0.8
1.24
N/A
0.97
10.04
0.37
Retained Earnings
(229.93 M)
(6.25 B)
(44.6 M)
(16.77 M)
(98.15 M)
(51.96 M)
(44.6 M)
(18.51 M)
(172.59 M)
(298.44 M)
Current Asset
34.86 M
N/A
N/A
8.46 M
N/A
N/A
N/A
N/A
19.16 M
9.64 M
Five Year Return
N/A
N/A
N/A
5.18
N/A
N/A
N/A
N/A
N/A
N/A
Beta
0.99
0.5
3.12
0.67
1.42
4.72
3.12
1.34
0.82
0.6
Number Of Employees
53
993
75
116
51
50
75
7
147
50
Shares Outstanding
2.21 M
31.62 M
15.48 M
5.89 M
1.48 M
4.39 M
N/A
380.65 K
4.27 M
2.63 M
Cash Flow From Operations
(18.41 M)
(460.2 M)
(6.04 M)
(1.48 M)
(3.56 M)
(9.57 M)
(6.04 M)
(4.73 M)
(8.72 M)
(13.29 M)
Total Debt
4.83 M
158.57 M
1.58 M
2.3 M
1.12 M
871.44 K
1.58 M
2.93 M
9.44 M
12.11 M
Return On Equity
-3.43
-0.92
-1.52
-0.61
-0.29
-1.72
-1.52
-1.14
-2.85
-1.87
Z Score
-20.86
-9.27
N/A
N/A
N/A
N/A
N/A
-3.84
-4.6
-15.64
Return On Asset
-0.62
-0.35
-0.7
-0.16
-0.19
-0.53
-0.7
-0.4
-0.26
-0.52
Number Of Shares Shorted
2.73 K
20.78 K
427.49 K
38.6 K
5.87 K
388.87 K
N/A
41.35 K
47.35 K
29.73 K
Book Value Per Share
0.21
17.9
0.3
1.15
10.16
2.41
0.52
8.4
-14.5
0.12
Current Liabilities
6.32 M
N/A
N/A
3.56 M
N/A
N/A
N/A
N/A
23.37 M
3.34 M
Total Asset
17.78 M
975.33 M
8.22 M
12.33 M
18.1 M
13.78 M
8.22 M
8.41 M
38.43 M
30.87 M
Debt To Equity
2.52
0.18
N/A
0.36
0.064
N/A
N/A
0.46
6.55
0.33
Short Ratio
0.03
0.29
1.43
0.79
0.59
1.25
N/A
1.86
0.19
0.05
Target Price
6.0
1.34
6.0
32.0
19.0
12.0
N/A
3.0
11.0
4.0
Last Dividend Paid
N/A
N/A
N/A
0.07
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
0.74
12.51
2.46
20.22
8.79
14.38
N/A
7.31
N/A
1.98
Market Capitalization
1.06 M
127.29 M
19.81 M
15.74 M
8.89 M
6.14 M
N/A
2.57 M
5.16 M
1.14 M
Price To Earning
-0.88
N/A
N/A
92.08
-1.14
N/A
N/A
N/A
-1.07
5.34
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.04
Price To Sales
1.06
0.2
1.65
0.76
0.57
2.44
N/A
37.72
0.1
0.2
Net Income
(21.59 M)
(810.63 M)
(7.94 M)
(4.15 M)
(5.85 M)
(10.19 M)
(7.94 M)
(5.62 M)
(14.94 M)
(32.09 M)
Earnings Per Share
-17.1
-3.62
-0.91
-0.51
-1.81
-2.3
N/A
-16.4
-3.12
-48.17
Shares Owned By Insiders
6.54
6.82
29.55
23.14
12.98
3.01
N/A
31.5
28.12
9.2
Revenue
6.37 M
650.71 M
2.53 M
22.1 M
15.2 M
3.11 M
2.53 M
N/A
41.31 M
25.86 M
Working Capital
7.38 M
319.08 M
1.72 M
2.1 M
541 K
3.08 M
1.72 M
5.41 M
(4.21 M)
10.84 M
Cash And Equivalents
14.1 M
472.68 M
214.4 K
1.79 M
7.47 M
8.28 M
214.4 K
7.85 M
1.86 M
27.57 M
Cash Per Share
1.28
5.1
0.08
0.32
0.33
0.56
0.08
0.66
0.44
1.63
Gross Profit
(2.01 M)
337.97 M
N/A
9.29 M
2.39 M
326.67 K
2.6 M
77.97 K
17.95 M
(2.58 M)
Day Typical Price
0.51
0.95
0.77
2.63
6.75
1.71
0.6
0.39
2.19
1.43
Accumulation Distribution
0.38
0.0408
10838.75
0.11
404.57
63155.77
N/A
0.0732
0.0091
0.17
Market Facilitation Index
0.23
0.04
0.0
0.31
1.0E-4
N/A
N/A
0.03
0.02
0.27
Daily Balance Of Power
0.8696
(0.50)
(0.08)
0.1935
0.9302
0.8182
(9,223,372,036,855)
N/A
N/A
0.6296
Period Momentum Indicator
0.2
(0.02)
(0.01)
0.06
0.4
0.18
(0.01)
N/A
N/A
0.17
Rate Of Daily Change
1.54
0.98
0.99
1.02
1.06
1.11
0.98
1.0
1.0
1.13
Day Median Price
0.49
0.96
0.77
2.62
6.69
1.69
0.6
0.4
2.19
1.42
Price Action Indicator
0.18
(0.03)
(0.02)
0.085
0.39
0.16
(0.01)
(0.01)
0.01
0.12
Coefficient Of Variation
(848.87)
7768.39
(849.38)
1457.34
4197.61
1915.68
2927.03
7064.62
819.2
(369.77)
Mean Deviation
9.08
1.87
3.73
1.52
2.18
3.97
11.52
4.56
10.38
6.16
Jensen Alpha
(1.53)
0.0244
(0.59)
0.4112
0.0776
0.0581
0.2153
0.0945
2.5
(2.61)
Total Risk Alpha
(3.07)
(0.26)
(1.23)
(0.22)
(0.24)
(0.31)
(1.44)
(0.72)
0.3124
(3.49)
Sortino Ratio
N/A
(0.02)
N/A
0.0545
(0.01)
0.0357
0.0341
0.0013
0.2095
N/A
Downside Variance
N/A
11.0
N/A
23.76
7.52
25.91
275.96
31.45
157.43
N/A
Standard Deviation
13.56
2.61
5.4
5.32
2.79
5.4
19.48
7.56
22.35
9.2
Kurtosis
2.32
1.46
2.17
37.36
0.1805
1.2
11.49
11.42
29.69
6.97
Potential Upside
25.0
3.45
11.27
1.74
5.26
9.93
28.21
12.5
18.81
9.24
Treynor Ratio
1.96
(2.40)
1.05
(0.57)
(0.24)
0.1144
0.1339
3.43
1.14
(2.01)
Maximum Drawdown
65.45
14.43
32.01
57.47
11.89
25.53
83.21
50.87
194.9
66.54
Variance
183.83
6.79
29.19
28.34
7.8
29.11
379.51
57.2
499.67
84.66
Market Risk Adjusted Performance
1.97
(2.39)
1.06
(0.56)
(0.23)
0.1244
0.1439
3.44
1.15
(2.00)
Risk Adjusted Performance
(0.09)
0.0175
(0.09)
0.0657
0.0269
0.052
0.0381
0.0207
0.1116
(0.22)
Skewness
0.0831
(0.15)
0.5578
4.02
0.3723
0.5346
2.44
2.51
4.58
(1.59)
Semi Deviation
N/A
2.49
N/A
3.35
2.6
4.67
13.27
4.49
9.49
N/A
Information Ratio
(0.13)
(0.03)
(0.14)
0.0499
(0.01)
0.0337
0.029
9.0E-4
0.1176
(0.28)
Value At Risk
(20.00)
(4.08)
(7.41)
(1.67)
(3.87)
(7.97)
(26.92)
(10.64)
(16.19)
(15.27)
Expected Short fall
N/A
(2.24)
N/A
(2.29)
(2.25)
(4.51)
(15.29)
(8.97)
(14.08)
N/A
Downside Deviation
N/A
3.32
N/A
4.87
2.74
5.09
16.61
5.61
12.55
N/A
Semi Variance
N/A
6.21
N/A
11.2
6.74
21.81
176.21
20.2
90.1
N/A

HTG Molecular Competition Performance Charts

Five steps to successful analysis of HTG Molecular Competition

HTG Molecular's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by HTG Molecular Diagnostics in relation to its competition. HTG Molecular's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of HTG Molecular in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact HTG Molecular's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to HTG Molecular Diagnostics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your HTG Molecular position

In addition to having HTG Molecular in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Obamacare Repeal Thematic Idea Now

Obamacare Repeal
Obamacare Repeal Theme
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Consideration for investing in HTG Stock

If you are still planning to invest in HTG Molecular Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the HTG Molecular's history and understand the potential risks before investing.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Transaction History
View history of all your transactions and understand their impact on performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY